A phase IIa multicenter, randomized, double-blind, double-dummy, and placebo- and active controlled study to investigate the safety and efficacy of JNJ-18038683 administered to subjects with major depressive disorder

Trial Profile

A phase IIa multicenter, randomized, double-blind, double-dummy, and placebo- and active controlled study to investigate the safety and efficacy of JNJ-18038683 administered to subjects with major depressive disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs JNJ 18038683 (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Dec 2010 Actual initiation date changed from 1 Nov 2007 to 1 Dec 2007 as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Actual initiation date changed from 1 Nov 2007 to 1 Dec 2007 as reported by ClinicalTrials.gov.
    • 05 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top